XLIMus Drug Eluting Stent: a randomIzed Controlled Trial to Assess Endothelization (XLIMIT)
Sponsor: Cardionovum GmbH
This NA trial investigates Coronary Artery Disease and is currently completed. Cardionovum GmbH leads this study, which shows 11 recorded versions since 2019 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Mar 2024 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Apr 2022 — Mar 2024 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Apr 2022 [monthly]
Recruiting NA
▶ Show 6 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Recruiting NA
-
Feb 2020 — Aug 2020 [monthly]
Recruiting NA
-
Jan 2020 — Feb 2020 [monthly]
Recruiting NA
-
Nov 2019 — Jan 2020 [monthly]
Recruiting NA
-
Apr 2019 — Nov 2019 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Dec 2018 — Apr 2019 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cardionovum GmbH
- Mediolanum Cardio Research
For direct contact, visit the study record on ClinicalTrials.gov .